We are pleased to announce that we entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software:– With Retina Pharmaceuticals in Ethiopia;– With Bionova in Bolivia ! ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email :
New distribution partnership in Ethiopia & Bolivia Read More »
We are pleased to announce that our DeepChek® Assay 13-Plex KB Drug Susceptibility Testing, intended to be used for Tuberculosis Drug Resistance assessment through NGS sequencing, is now CE-IVD marked ! ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email : contact@abldiagnostics.com Email 2 : fauvet-girel@ablsa.com Envelope
DEEPCHEK® ASSAY 13-PLEX KB DRUG SUSCEPTIBILITY TESTING IS NOW CE-IVD MARKED Read More »
We are pleased to announce a new poster presentation entitled “Evaluation of a commercial assay whole genome HIV-1 using next-generation sequencing” at ECCMID 2022. Link to the poster presentation. Please feel free to contact us to get more information. ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061
Presentation of the DeepChek®-HIV Whole Genome Assay at ECCMID 2022 Read More »
ETABLISSEMENTS FAUVET GIREL (FR0000063034 – FAUV – Euronext Paris) publie ses résultats annuels au titre de l’exercice clos le 31 décembre 2021, arrêtés par le Conseil d’administration du 8 février 2022. Les comptes ont été audités par le commissaire aux comptes dont le rapport de certification est en cours d’émission. Résultats annuels 2021 ETABLISSEMENTS FAUVET
ÉTABLISSEMENTS FAUVET GIREL – RÉSULTATS ANNUELS 2021 Read More »
Advanced Biological Laboratories (ABL) S.A. and Geneplus Co Ltd are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Thailand See all the current Distributors ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone :
ABL announce a new Distribution Agreement with Geneplus Co Ltd in Thailand Read More »
L’offre publique d’achat simplifiée visant les actions ETABLISSEMENTS FAUVET-GIREL, initiée le23 décembre 2021 par ADVANCED BIOLOGICAL LABORATORIES SA (« ABL SA »), s’est clôturée le 7 janvier 2022. A l’occasion de cette offre, ABL SA a acquis 954 actions représentant 0,38% du capital et 0,38% des droits de vote de la société ETABLISSEMENTS FAUVET-GIREL. À la clôture de
Advanced Biological Laboratories (ABL) S.A. and Hayleys Lifesciences are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Sri Lanka. See all the current Distributors ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone :
ABL Announces Distribution Agreement with Hayleys Lifesciences in Sri Lanka Read More »
The Luxembourg Institute of Health (LIH) and Advanced Biological Laboratories (ABL) are joining forces to predict immune protection against COVID-19 and support long-term vaccination strategies. To this end, the two laboratories have signed a license agreement and a collaboration agreement to provide two in vitro diagnostic solutions to measure neutralizing antibody levels. LIH has established a
ABL announces Distribution Agreement with Medsol in Saudi Arabia Advanced Biological Laboratories (ABL) S.A. and Medsol Corporation are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Saudi Arabia. See current channel partners. Find us on: ABL DIAGNOSTICS 42,
ABL ANNOUNCES DISTRIBUTION AGREEMENT WITH MEDSOL IN SAUDI ARABIA Read More »
